



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: William W. Alston et al.) Atty. Docket No.: 0136.00
)
) Examiner: Ali, Shumaya B.
)
Application No.: 10/729,832) Group Art Unit: 3743
)
Filed: December 5, 2003)
)
Title: RECEPTACLE FOR AN)
AEROSOLIZABLE)
PHARMACEUTICAL FORMULATION)

)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450 Alexandria, Virginia 22313-1450 on *Nov. 18, 2005*

Signed: Minia Cottar

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Dear Sir:

The references listed in the attached Form PTO/SB/08A may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

In compliance with 37 CFR §§1.98 U.S. patents will be provided upon request by the Office.

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

- within three months of the filing date of a national application or an RCE; within three months of the date of entry of the national stage as set forth in section 1.491 in an international application; or before the mailing date of a first Office action on the merits (whichever event occurs last);
- more than three months from the filing date of an application and after the mailing date of a first Office action on the merits, but before the mailing date of either a final action under section 1.113 or a notice of allowance under section 1.311 (whichever occurs first), and is accompanied by:
 - the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00)
- Please charge the amount of \$180.00 to Deposit Account 500348
- If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500348.

Respectfully submitted,

NEKTAR THERAPEUTICS

Dated: 19 Nov 2005

By:



Guy V. Tucker
Reg. No. 45,302

San Carlos, CA 94070
(650) 631-3100

Form PTO/SB/08A (Modified)	Atty Docket No.: 0136.00	Application No.: 10/729,832
Information Disclosure Statement By Applicant <i>(Use Several Sheets if Necessary)</i>		
Applicant: William W. Alston et al.		
Filing Date: 12/05/2003		Group: 3743

U.S. Patent Documents

Examiner:	Date Considered:
------------------	-------------------------

Examiner: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.